Package 'SurrogateSeq'

January 23, 2024

Title Assessing Heterogeneity in Surrogacy Using Censored Data

Type Package

Version 1.0

Description

Author Layla Parast, Jay Bartroff

Description																																
-	nplement group sequential procedures that allow for early stopping to de-														e-																	
clare efficacy using a surrogate marker and the possibility of																																
		the future in: Parast, L. and Bartroff, J (2024) ``Group Sequential Test-																														
ing of																,				,				Г		1						
License GPL																																
Imports sta	ts, MASS, ggp	loť	2																													
NeedsCompilation no																																
Depends R	(>= 3.5.0)																															
R topics	documen	te	d:																													
del	ta.e.estimate .																															1
	mple.data																															
	boundaries																															
_	boundaries.fut																															5
Stu	ıdyA.aids																															6
Stu	ıdyB.aids																															7
Index																																8
delta.e.	estimate		Tes ma	•							ej	ffe	ect	OF	n t	the	e p	ri	ma	ry	oı	utc	con	ne	и	sir	ıg	sı	ırr	og	ate	

Nonparametric test for a treatment effect on the primary outcome using surrogate marker information. This test borrows information from a prior study (Study A) about the relationship between the surrogate and the primary outcome to test for a treatment effect in the current study (Study B).

2 delta.e.estimate

Usage

```
delta.e.estimate(sone = NULL, szero = NULL, szerop, yzerop, extrapolate = TRUE, mat = NULL, n1 = NULL, n0 = NULL)
```

Arguments

sone	surrogate marker in the treated group in Study B
szero	surrogate marker in the control group in Study B
szerop	surrogate marker in the control group in Study A
yzerop	primary outcome in the control group in Study A
extrapolate	TRUE or FALSE; extrapolate for values outside of the support in Study A
mat	for Study B, the user can either provide sone and szero or can provide a vector, mat, where the first $n1$ values are the surrogate marker in the treated group in the Study B, and the remaining values are the surrogate marker in the control group in Study B
n1	sample size of treated group in Study R: only needed if mat is provided instead

n1 sample size of treated group in Study B; only needed if mat is provided instead

of sone and szero

no sample size of control group in Study B; only needed if mat is provided instead

of sone and szero

Value

delta.e	estimated treatment effect using surrogate marker information
sd.closed	estimated standard error of treatment effect estimate
delta.e.z	test statistic
delta.e.p	p-value of test statistic

Author(s)

Layla Parast

References

Parast, Cai, and Tian (2023). Using a Surrogate with Heterogeneous Utility to Test for a Treatment Effect. Statistics in Medicine, 42(1): 68-88.

Parast and Bartroff (2023+). Group Sequential Testing of a Treatment Effect Using a Surrogate Marker. Under Review.

Examples

```
data(example.data)
delta.e.estimate(sone = example.data$s1, szero = example.data$s0, szerop = example.data$s0.p,
yzerop = example.data$y0.p)

data(StudyA.aids)
data(StudyB.aids)
s1.studyb = StudyB.aids$s1
s0.studyb = StudyB.aids$s0
s0.studya = StudyA.aids$s0
```

example.data 3

```
#24 weeks
```

```
delta.e.vec = delta.e.estimate(sone=s1.studyb$CD4_24weeks[!is.na(s1.studyb$CD4_24weeks)],
szero=s0.studyb$CD4_24weeks[!is.na(s0.studyb$CD4_24weeks)], szerop = s0.studya$CD4_24weeks,
yzerop = StudyA.aids$y0, extrapolate = TRUE)
delta.e.vec
```

example.data

Example data

Description

Example data

Usage

```
data("example.data")
```

Format

A list with 9 elements:

```
w0.p the baseline covariate in the control group in the prior study (Study A)
```

s0.p the surrogate marker in the control group in the prior study (Study A

y0.p the primary outcome in the control group in the prior study (Study A

w1 a baseline covariate in the treatment group in the current study (Study B)

wo a baseline covariate in the control group in the current study (Study B)

s1 the surrogate marker in the treatment group in the current study (Study B)

s0 the surrogate marker in the control group in the current study (Study B)

y1 the primary outcome in the treatment group in the current study (Study B)

yo the primary outcome in the control group in the current study (Study B)

Examples

```
data(example.data)
names(example.data)
```

4 gs.boundaries

gs.boundaries	Computes group sequential boundaries	
---------------	--------------------------------------	--

Description

Computes group sequential (and naive) boundaries for the nonparametric test for a treatment effect on the primary outcome using surrogate marker information. The boundaries and test statistic borrow information from a prior study (Study A) about the relationship between the surrogate and the primary outcome to test for a treatment effect in the current study (Study B).

Usage

```
gs.boundaries(szerop, sonep, yzerop, n.stg, B.norm = 1e+06, alpha = 0.05, pp = 0.4, inf.fraction = (1:n.stg)/n.stg, plot=FALSE)
```

Arguments

szerop	surrogate marker in the control group in Study A
sonep	surrogate marker in the treated group in Study A
yzerop	primary outcome in the control group in Study A
n.stg	maximum number of analyses

B. norm number of multivariate normal vectors to use in simulation for boundaries; de-

fault is 1e+06

alpha desired rejection probability of the test; default is 0.05 pp power parameter for Wang-Tsiatis boundaries; default is 0.4

inf. fraction information fraction vector of the same length as n.stg which reflects the fraction

of information at each analysis, should be positive, non-decreasing, and the last entry should be 1; default is (1:n.stg)/n.stg, user may want to specify a different

vector for unequal time points

plot TRUE or FALSE if a plot of the boundaries is desired; default is FALSE

Value

Returns a list of boundaries:

Naive Naive boundaries

Bonf Bonferroni boundaries

Pocock Pocock boundaries

OBrien_Fleming O'Brien-Fleming boundaries
Wang_Tsiatis Wang-Tsiatis boundaries

Author(s)

Layla Parast and Jay Bartroff

References

Parast and Bartroff (2023+). Group Sequential Testing of a Treatment Effect Using a Surrogate Marker. Under Review.

gs.boundaries.fut 5

Examples

```
data(example.data)
data(StudyA.aids)
data(StudyB.aids)
s0.studya = StudyA.aids$s0
s1.studya = StudyA.aids$s1

bound = gs.boundaries(szerop = s0.studya, sonep = s1.studya, yzerop=StudyA.aids$y0, n.stg=4, B.norm=1e6, alpha=0.05)

bound
```

gs.boundaries.fut

Computes group sequential boundaries with futility stopping

Description

Computes group sequential (and naive) boundaries for the nonparametric test for a treatment effect on the primary outcome using surrogate marker information. The boundaries and test statistic borrow information from a prior study (Study A) about the relationship between the surrogate and the primary outcome to test for a treatment effect in the current study (Study B). The group sequential boundaries allow for futility stopping (bounds given).

Usage

```
gs.boundaries.fut(szerop, sonep, yzerop, n.stg, B.norm = 1e+06, alpha = 0.05, pp = 0.4, inf.fraction = (1:n.stg)/n.stg, j.star=1, alpha0=(j.star/n.stg)*alpha, plot = FALSE)
```

Arguments

szerop	surrogate marker in the control group in Study A
sonep	surrogate marker in the treated group in Study A
yzerop	primary outcome in the control group in Study A
n.stg	maximum number of analyses
B.norm	number of multivariate normal vectors to use in simulation for boundaries; default is $1\text{e}+06$
alpha	desired rejection probability of the test; default is 0.05
pp	power parameter for Wang-Tsiatis boundaries; default is 0.4
inf.fraction	information fraction vector of the same length as n.stg which reflects the fraction of information at each analysis, should be positive, non-decreasing, and the last entry should be 1; default is (1:n.stg)/n.stg, user may want to specify a different vector for unequal time points
j.star	earliest stage at which futility stopping is allowed. Should be <= n.stg-1 (there is already "futility stopping" at the n.stg-th stage anyway). Default is 1.
alpha0	the part of alpha that c1 is chosen to spend in first j.star stages; default is (j.star/n.stg)*alpha
plot	TRUE or FALSE if a plot of the boundaries is desired; default is FALSE

6 StudyA.aids

Value

Returns a list of boundaries:

Naive Naive boundaries

Bonf Bonferroni boundaries

Pocock.futility

Pocock futility boundaries

Pocock.nullrejection

Pocock null rejection boundaries

OBrien_Fleming.futility

O'Brien-Fleming futility boundaries

OBrien_Fleming.nullrejection

O'Brien-Fleming null rejection boundaries

Wang_Tsiatis.futility

Wang-Tsiatis futility boundaries

Wang_Tsiatis.nullrejection

Wang-Tsiatis null rejection boundaries

Author(s)

Layla Parast and Jay Bartroff

References

Parast and Bartroff (2023+). Group Sequential Testing of a Treatment Effect Using a Surrogate Marker. Under Review.

Examples

```
data(example.data)
data(StudyA.aids)
data(StudyB.aids)
s0.studya = StudyA.aids$s0
s1.studya = StudyA.aids$s1

bound = gs.boundaries.fut(szerop = s0.studya, sonep = s1.studya, yzerop=StudyA.aids$y0, n.stg=4, B.norm=1e6, alpha=0.05)

bound
```

StudyA.aids

ACTG 320 clinical trial data

Description

Primary outcome and surrogate marker measurements over time from the ACTG 320 clinical trial data

Usage

```
data("StudyA.aids")
```

StudyB.aids 7

Format

A list with 4 elements:

y1 the primary outcome in the treatment group in Study A; the primary outcome is defined as -1 times (log of RNA at 40 weeks - log of RNA at baseline) because a DECREASE in RNA is better

- yo the primary outcome in the control group in Study A
- s1 a dataframe of the surrogate markers at different time points in the treatment group in Study A; the surrogate marker is change in CD4 cell count from baseline to 4 weeks (CD4_4weeks), 8 weeks (CD4_8weeks), 24 weeks (CD4_24weeks), and 40 weeks (CD4_40weeks). Note that higher values indicate increasing CD4 cell count which is "better".
- so a dataframe of the surrogate markers at different time points in the control group in Study A

Examples

data(StudyA.aids)

StudyB.aids

ACTG 193A clinical trial data

Description

Surrogate marker measurements over time from the ACTG 193A clinical trial data. Note that the time points do not exactly match up to ACTG 320. In the paper, we use Study A surrogate data at 24 weeks to construct the conditional mean function applied to Study B at 16 weeks. Also note that some subjects are missing values of the surrogate at one or more time points. The naive estimate of the treatment effect using the surrogates uses all non-missing data available at each time point.

Usage

```
data("StudyB.aids")
```

Format

A list with 2 elements:

- s1 a dataframe of the surrogate markers at different time points in the treatment group in Study B; the surrogate marker is change in CD4 cell count from baseline to 8 weeks (CD4_8weeks), 16 weeks (CD4_16weeks), 24 weeks (CD4_24weeks), and 40 weeks (CD4_40weeks). Note that higher values indicate increasing CD4 cell count which is "better".
- so a dataframe of the surrogate markers at different time points in the control group in Study B

Examples

```
data(StudyB.aids)
```

Index

```
* boundaries
    gs.boundaries,4
    gs.boundaries.fut,5
* datasets
    StudyA.aids, 6
    StudyB.aids, 7
* futility
    \mathsf{gs.boundaries.fut}, 5
* nonparametric
    {\tt delta.e.estimate}, \\ 1
    gs.boundaries, 4
    gs.boundaries.fut, 5
* test
    {\tt delta.e.estimate, 1}
    gs.boundaries, 4
    gs.boundaries.fut, 5
delta.e.estimate, 1
example.data, 3
{\tt gs.boundaries,4}
gs.boundaries.fut,5
{\sf StudyA.aids}, {\color{red} 6}
StudyB.aids, 7
```